Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

clinical_trial_3

Celator receives FDA breakthrough therapy designation for leukaemia drug

May 20, 2016 Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …
News

Urgent action needed on antimicrobial resistance, says government report

May 19, 2016 Manufacturing and Production, Medical Communications, Research and Development ABPI, Lord Jim O'Neill, NICE, antimicrobial resistance

A new UK governmental report has warned that the global rise of antimicrobial resistance is set to worsen, with the …
News
clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016 Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
News
bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016 Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016 Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
News

AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016 Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016 Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
News

Novartis splits pharmaceuticals division into two business units

May 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …
News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
News
michael_becker

Relmada Therapeutics appoints new chief financial officer

May 17, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing chief financial officer, relmada

Michael D. Becker has been appointed the new chief financial officer at Relmada Therapeutics. Becker joined the company in 2014 …
Appointment
biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016 Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
News
astrazeneca_plaque

AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial

May 17, 2016 Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial

UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …
News
stocks3

Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …
News
mylan_building

Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016 Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026